Industry Timetable

Print
Satellite Symposia Timetable
Friday May 11, 2018
10:50-11:50 | Hall A | Satellite Symposium A
Supported by Novo Nordisk

Chairperson: Shan Zhongyan, China
T2DM patients can't bear the burden of the "weight": Qu Shen, China
10:50-11:50 | Hall B | Satellite Symposium B
Supported by MSD

Chairperson: Ning Guang, China
T2
differentiation of DPP-4is – Learning from CDS new guideline: Wang Weiqing, China
Sitagliptin add-on to insulin—insulin sparling, strong HbA1c reductions: Peng Yongde, China
10:50-11:50 | Hall C | Satellite Symposium C
Supported by Servier

Chairpersons:  Zhu Dalong, China and Wang Weiqing, China
Sulphonylurea And β Cell Dedifferentiation: Li Yanbing, China
The Clinical Value Of Sulfornylureas In Type 2 Diabetes Management In China: Zou Dajin, China
12:00-13:00 | Hall A | Satellite Symposium D
Supported by Novo Nordisk

Chairperson: Shi Yongquan, China and Huang Qin, China
A new clinical guidance of insulin switching: how to switch insulin regimen normatively: Shi Yongquan, China
Insulin treatment strategy from Chinese guideline, evident, and practice:  Huang Qin, China
12:00-12:30 | Hall B | Satellite Symposium E
Supported by Abbott

Chairperson: Ning Guang, China
Ambulatory glucose profile (AGP) - An evidence-based approach to clinical decision-making: Yan Li, China

 12:00-12:30 | Hall B | Satellite Symposium E

Supported by Novartis

Chairperson: Wang Weiqing, China
T2DM early combination therapy - clinical experience sharing from Taiwan: Wang Zhiyuan, China
 
12:00-13:00 | Hall C | Satellite Symposium F
Supported by 3Sbio

Chairpersons: Ning Guang, China and Chen Lulu, China
Once-weekly Bydureon or Basal Insulin?: Wang Weiqing, China
Microsphere Technology Makes Patients Enjoy Once-weekly Injection: Zou Dajin, China
 
14:30-15:30 | Hall A | Satellite Symposium G
Supported by Bayer

Chairperson: Wang Weiqing, China
What happens in the gut after takeing acarbose?: Tong Nanwei, China From ACE to MARCH: Li Yanbing, China
 
14:30-15:30 | Hall B | Satellite Symposium H
Supported by Eli Lilly

Chairpersons: Ji Linong, China and Zhu Dalong, China
Keeping up with the times, everlasting new- interpreting CDS guideline’s  update:  Peng Yongde, China
 
14:30-15:30 | Hall C | Satellite Symposium I
Supported by AstraZeneca

Chairperson: Mu Yiming, China
Truth from clinical practice – Saxagliptin stands out from the rest: Shi Yongquan, China
Decoding 3.0 Generation of OAD -Diabetes Management Revolution: Qu Shen, China
Saturday May 12, 2018
12:30-13:30 | Hall A | Satellite Lunch Symposium J
Supported by Pfizer

Chairperson: Ning Guang, China
Lipid target management strategy of diabetic patients: Wang Weiqing, China
Are all statins the same? From the perspective of inflammation: Lu Lin, China
12:30-13:30 | Hall A | Satellite Lunch Symposium K
Supported by Eli Lilly

Chairperson: Peng Yongde, China and Zhu Dalong, China
The strategy of prevention and control of diabetes: Lu Hao, China
Comprehensive management of diabetes with other chronic diseases:  Qin Li, China
12:30-13:30 | Hall A | Satellite Lunch Symposium L
Supported by CR Double Crane

Chairpersons: Wang Weiqing, China and Zou Dajin, China
To investigate the choice of oral hypoglycemic agents in the treatment of diabetic nephropathy from basic experiments to clinical studies: Chen Li, China